Sendai Virus-Based Oncolytic Gene Therapy

Morodomi, Yosuke; Hasegawa, Mamoru; Okamoto, Tatsuro; Maehara, Yoshihiko; Yonemitsu, Yoshikazu

doi:10.5772/55328

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A group of viruses commonly used in medical and veterinary research was selected to cover different aspects of viral pathogenesis. Sendai virus is frequently used as a model for entry of enveloped viruses into animal cells [6,21]. Newcastle Disease Virus has well researched antineoplastic and pleiotropic immune responses [17].…”

Section: Virusesmentioning

confidence: 99%

New functionally-enhanced soy proteins as food ingredients with anti-viral activity

et al. 2015

View full text Add to dashboard Cite

Respiratory viruses are a major public health problem because of their prevalence and high morbidity rate leading to considerable social and economic implications. Cranberry has therapeutic potential attributed to a comprehensive list of phytochemicals including anthocyanins, flavonols, and unique A-type proanthocyanidins. Soy flavonoids, including isoflavones, have demonstrated anti-viral effects in vitro and in vivo. Recently, it was demonstrated that edible proteins can efficiently sorb and concentrate cranberry polyphenols, including anthocyanins and proanthocyanins, providing greatly stabilized matrices suitable for food products. The combination of cranberry and soy phytoactives may be an effective dietary anti-viral resource. Anti-viral properties of both cranberry juice-enriched and cranberry pomace polyphenol-enriched soy protein isolate (CB-SPI and CBP-SPI) were tested against influenza viruses (H7N1, H5N3, H3N2), Newcastle disease virus and Sendai virus in vitro and in ovo. In our experiments, preincubation with CB-SPI or CBP-SPI resulted in inhibition of virus adsorption to chicken red blood cells and reduction in virus nucleic acid content up to 16-fold, however, CB-SPI and CBP-SPI did not affect hemagglutination. Additionally, CB-SPI and CBP-SPI inhibited viral replication and infectivity more effectively than the commercially available anti-viral drug Amizon. Results suggest CB-SPI and CBP-SPI may have preventative and therapeutic potential against viral infections that cause diseases of the respiratory and gastro-intestinal tract.

show abstract

Section: Virusesmentioning

confidence: 99%

New functionally-enhanced soy proteins as food ingredients with anti-viral activity

et al. 2015

View full text Add to dashboard Cite

show abstract

BioKnife, a Modified Sendai Virus, to Resect Malignant Tumors

Yonemitsu

Ueda

Hasegawa

2013

Sendai Virus Vector

View full text Add to dashboard Cite

Reduced pathogenicity of velogenic NDV strain AF22420-I via site-directed mutagenesis of V gene

Lee

Kalyanasunandram

Murulitharan

et al. 2021

APJMBB

View full text Add to dashboard Cite

Newcastle disease virus (NDV), an avian paramyxovirus, has the potential to be used as an anti-cancer therapeutic vaccine due to its oncolytic and immunostimulatory activities. The virus can be categorised into three pathotypes: lentogenic, mesogenic, and velogenic; of the three pathotypes, the lentogenic strains such as the La Sota are the preferred pathotype for vaccine development due to their low virulence to birds. On the other hand, the translation of the virus to clinic of the velogenic strain AF2240-I is hindered by its virulence towards birds although it exhibits strong oncolysis with significant outcomes both in vitro and in vivo. This study aims to reduce the pathogenicity of AF2240-I yet retaining the anti-cancer properties of the virus. To achieve this, the V protein that acts as an interferon antagonist was chosen to be mutated. It is a non-structural protein that does not interfere with the binding and infection of the virus; hence, mutation of this virulence factor was deducted to be able to reduce harm to the avian species but retain its anti-cancer properties as much as possible. The V protein, which was produced from the insertion of an additional G into a conserved editing site of the P gene, was mutated by substituting the G nucleotide at position 411 from the start of P gene to a T nucleotide. This mutation will produce a premature stop codon from the V mRNA, resulting in a truncated V protein; but only causes a silent mutation in the P protein. The recombinant virus was recovered by the use of BHK cells stably expressing the phage T7 RNA polymerase. The pathogenicity of the mutated virus was determined in 9- to 11-day-old embryonated SPF chicken eggs. The mean death time (MDT) was determined to be 73.6 hours at the minimal lethal dose of 10-7, resembling to that of a mesogenic strain. The virulence of the mutated virus has been successfully reduced where it could be potentially used as the vector for the development of recombinant oncolytic virus for cancer treatment.

show abstract

Sendai Virus-Based Oncolytic Gene Therapy

Cited by 3 publications

References 30 publications

New functionally-enhanced soy proteins as food ingredients with anti-viral activity

New functionally-enhanced soy proteins as food ingredients with anti-viral activity

BioKnife, a Modified Sendai Virus, to Resect Malignant Tumors

Reduced pathogenicity of velogenic NDV strain AF22420-I via site-directed mutagenesis of V gene

Contact Info

Product

Resources

About